Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is facing a securities suit after amending its analysis of the Phase 3 Fianlimab+Libtayo melanoma trial—which missed PFS on May 15, 2026—while co‑founder George Yancopoulos announced a free gene therapy to restore hearing in children with a rare genetic deafness.
Previous Week Recap
- Regeneron Faces Securities Suit: Regeneron (REGN) faces a securities suit after it amended analysis for the Phase 3 Fianlimab+Libtayo melanoma trial, citing slow event rates; May 15, 2026: trial missed PFS significance.
- Regeneron Co-Founder Announces Free Gene Therapy: Regeneron’s co‑founder George Yancopoulos says the company developed a gene therapy to restore hearing in children with a rare genetic deafness and will offer it free of charge.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.